Fluetizolam

Fluetizolam is a synthetic thienotriazolodiazepine related to etizolam. Its structure differs from etizolam by the halogen attached to the phenyl ring: fluetizolam has fluorine where etizolam has chlorine. It has been identified in a small number of forensic samples, but published information about its pharmacology, metabolism and effects in humans is extremely limited.

Chemistry and identification

Fluetizolam retains the fused thienotriazolodiazepine framework of etizolam. The replacement of chlorine with fluorine is a relatively small structural change, but it can affect the way a compound interacts with biological targets and is metabolised.

The Center for Forensic Science Research and Education reported fluetizolam in a plasma sample received in October 2022. The sample came from a clinical case in Los Angeles and also contained pentylone, 3-hydroxyphencyclidine and 4-methoxyphencyclidine. The presence of several psychoactive substances means that the case cannot establish which effects, if any, were caused by fluetizolam (CFSRE toxicology report, 2022).

Pharmacology

Fluetizolam is classified as a novel benzodiazepine. On structural grounds, it is expected to act at the benzodiazepine site of the GABA_A receptor, but no published receptor-binding or functional study has established its activity. The UK Advisory Council on the Misuse of Drugs noted in its 2024 review that there was no published information on the pharmacology or toxicology of fluetizolam at that time (ACMD, 2024 update).

Reported effects

Verified descriptions of fluetizolam are too scarce to establish a characteristic experience. Its similarity to etizolam suggests that benzodiazepine-like effects are possible, including sedation, reduced anxiety, muscle relaxation and impaired memory. These are expectations based on structure, not effects confirmed in controlled studies of fluetizolam.

Toxicity and research limitations

The available forensic record is too small to establish an acute toxicity profile. The single clinical sample reported by CFSRE contained several other psychoactive substances, and the symptoms cannot be attributed to fluetizolam alone on that basis.

No human pharmacokinetic study has established its metabolism or elimination. Dependence, withdrawal and interactions are also uncharacterised. The risks associated with other benzodiazepines, particularly when combined with opioids or alcohol, are relevant as general class concerns but should not be presented as fluetizolam-specific findings.

Related compounds

Fluetizolam is closely related to Etizolam and Deschloroetizolam. It should be distinguished from fluclotizolam, which has a different halogen substitution pattern.